Oncology News | pharmaphorum

News

AZ has another setback with Truqap after failed TNBC trial

AstraZeneca’s first-in-class pan-AKT inhibitor Truqap was unable to improve overall survival (OS) in a phase 3 trial in triple-negative breast cancer (TNBC), denting the prospects of the ne

News

Study finds low secondary cancer risk with CAR-Ts

There’s no doubt that CAR-T therapies have transformed the treatment of many blood cancers, but a risk of secondary malignancies has cast a pall over the class.

News

New data at EHA backs Sanofi, Innate’s NK cell engager

One of the lead candidates in Sanofi natural killer (NK) cell engager alliance with Innate Pharma has shown encouraging and durable efficacy in various haematological cancers, according to

News

AZ’s Calquence extends disease-free survival in MCL

AstraZeneca’s Calquence has been shown to improve progression-free survival in previously untreated mantle cell lymphoma (MCL), with an unprecedented trend towards improved overall survival

News

FDA widens label for BMS’ cancer drug Augtyro

Bristol-Myers Squibb has claimed FDA approval for a new, tumour-agnostic indication for Augtyro, the cancer drug it acquired as part of its $4.1 billion takeover of Turning Point Therapeuti

News

GSK et al file appeal to Delaware Zantac order

GSK and other drugmakers have lost no time in filing an appeal to a Delaware court’s decision to allow more than 70,000 Zantac-related lawsuits to go ahead.

AZ has another setback with Truqap after failed TNBC trial

Study finds low secondary cancer risk with CAR-Ts

New data at EHA backs Sanofi, Innate’s NK cell engager

AZ’s Calquence extends disease-free survival in MCL

FDA widens label for BMS’ cancer drug Augtyro

GSK et al file appeal to Delaware Zantac order

On genomics, NGS, and doing much more good than bad, with Ma...

How to meet your physicians where they are online

News

Editor's Picks